Soleno Therapeutics Inc (NASDAQ: SLNO) on Tuesday, plunged -0.18% from the previous trading day, before settling in for the closing price of $50.14. Within the past 52 weeks, SLNO’s price has moved between $36.61 and $60.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 37.06%. With a float of $33.47 million, this company’s outstanding shares have now reached $45.70 million.
The extent of productivity of a business whose workforce counts for 92 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Soleno Therapeutics Inc (SLNO) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Soleno Therapeutics Inc is 27.00%, while institutional ownership is 90.83%. The most recent insider transaction that took place on Jan 02 ’25, was worth 114,431. In this transaction an insider of this company sold 2,520 shares at a rate of $45.41, taking the stock ownership to the 78,945 shares. Before that another transaction happened on Jan 03 ’25, when Company’s insider sold 2,340 for $46.18, making the entire transaction worth $108,053. This insider now owns 76,605 shares in total.
Soleno Therapeutics Inc (SLNO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.06% per share during the next fiscal year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Soleno Therapeutics Inc (SLNO) is currently performing well based on its current performance indicators. A quick ratio of 15.68 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.26, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
The latest stats from [Soleno Therapeutics Inc, SLNO] show that its last 5-days average volume of 0.96 million was superior to 0.54 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 81.13%. Additionally, its Average True Range was 2.38.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 44.03%, which indicates a significant decrease from 79.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.97% in the past 14 days, which was lower than the 47.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.80, while its 200-day Moving Average is $48.63. Now, the first resistance to watch is $51.45. This is followed by the second major resistance level at $52.86. The third major resistance level sits at $53.83. If the price goes on to break the first support level at $49.07, it is likely to go to the next support level at $48.10. The third support level lies at $46.69 if the price breaches the second support level.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
Market capitalization of the company is 2.30 billion based on 45,857K outstanding shares. Right now, sales total 0 K and income totals -175,850 K. The company made 0 K in profit during its latest quarter, and -55,980 K in sales during its previous quarter.
